ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong

Lee, Sharen; Zhou, Jiandong; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Jeevaratnam, Kamalan; King, Emma; Liu, Tong; Wong, Wing Tak; Chang, Carlin; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Tse, Gary*; Zhang, Qingpeng*univ hong kong; tianjin med univ; chinese univ hong kong; cuhk
Cardiovascular Drugs and Therapy2023-6DOI: 10.1007/s10557-022-07319-x
18被引8阅读
引用收藏
分享

摘要

Objective To compare the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in Hong Kong. Methods This was a retrospective population-based cohort study of type 2 diabetes mellitus patients (n = 72,746) treated with SGLT2I or DPP4I between January 1, 2015, and December 31, 2020, in Hong Kong. Patients with exposure to both DPP4I and SGLT2I therapy, without complete demographics or mortality data, or who had prior atrial fibrillation (AF) were excluded. The study outcomes were new-onset AF, stroke/transient ischemic attack, cardiovascular mortality and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I users was performed. Results The unmatched study cohort included 21,713 SGLT2I users and 39,510 DPP4I users (total: n = 61,233 patients; 55.37% males, median age: 62.7 years [interquartile range (IQR): 54.6-71.9 years]). Over a median follow-up of 2030 (IQR: 1912-2117) days, 2496 patients (incidence rate [IR]: 4.07%) developed new-onset AF, 2179 patients (IR: 3.55%) developed stroke/transient ischemic attack, 1963 (IR: 3.20%) died from cardiovascular causes and 6607 patients (IR: 10.79%) suffered from all-cause mortality. After propensity score matching (SGLT2I: n = 21,713; DPP4I: n = 21,713), SGLT2I users showed lower incidence of new-onset AF (1.96% vs. 2.78%, standardized mean difference [SMD] = 0.05), stroke (1.80% vs. 3.52%, SMD = 0.11), cardiovascular mortality (0.47% vs. 1.56%, SMD = 0.11) and all-cause mortality (2.59% vs. 7.47%, SMD = 0.22) compared to DPP4I users. Cox regression found that SGLT2I users showed lower risk of new-onset AF (hazard ratio [HR]: 0.68, 95% confidence interval [CI]: [0.56, 0.83], P = 0.0001), stroke (HR: 0.64, 95% CI: [0.53, 0.79], P < 0.0001), cardiovascular mortality (HR: 0.39, 95% CI: [0.27, 0.56], P < 0.0001) and all-cause mortality (HR: 0.44, 95% CI: [0.37, 0.51], P < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory tests. Conclusions Based on real-world data of type 2 diabetic patients in Hong Kong, SGLT2I use was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4I use.

学科与关键词

关键词
Sodium-glucose cotransporter-2 inhibitorsDipeptidyl peptidase-4 inhibitorsDiabetesAtrial fibrillationStrokeCardiovascular mortalityAll-cause mortality
相关
加载中…
  • Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users
    Zhou, Jiandong; Lee, Sharen; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Liu, Tong; Liu, Ying; Chang, Dong; Wong, Wing Tak; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Zhang, Qingpeng*; Tse, Gary*ESC Heart Failure, 2022, 9(2): 1388-1399.被引 13
  • Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
    Zhou, Jiandong; Liu, Xuejin; Chou, Oscar Hou-In; Li, Lifang; Lee, Sharen; Wong, Wing Tak; Zhang, Qingpeng; Chang, Carlin; Liu, Tong; Tse, Gary; Jing, Fengshi*; Cheung, Bernard Man Yung*RHEUMATOLOGY, 2023, 62(4): 1501-1510.被引 12
  • Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study
    Chung, Cheuk To; Lakhani, Ishan; Chou, Oscar Hou In; Lee, Teddy Tai Loy; Dee, Christopher; Ng, Kendrick; Wong, Wing Tak; Liu, Tong; Lee, Sharen; Zhang, Qingpeng; Cheung, Bernard Man Yung; Tse, Gary*; Zhou, Jiandong*Cancer Medicine, 2023, 12(11): 12299-12315.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cardiovascular Drugs and Therapy
发表日期
2023-06
卷期
第 37 卷, 第 3 期
页码
561-569
DOI
10.1007/s10557-022-07319-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China (NSFC) [71972164]

作者

  • L

    Lee, Sharen (第一作者)

  • Z

    Zhou, Jiandong

查看全部 13 位作者收起作者
  • L

    Leung, Keith Sai Kit

    univ hong kong

  • W

    Wai, Abraham Ka Chung

    univ hong kong

  • J

    Jeevaratnam, Kamalan

  • K

    King, Emma

  • L

    Liu, Tong

    tianjin med univ

  • W

    Wong, Wing Tak

    chinese univ hong kong · cuhk

  • C

    Chang, Carlin

  • W

    Wong, Ian Chi Kei

    univ hong kong

  • C

    Cheung, Bernard Man Yung

    univ hong kong

  • T

    Tse, Gary (通讯)

    tianjin med univ

  • Z

    Zhang, Qingpeng (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417